外周血T细胞亚群检测在恶性肿瘤中的价值被引量：21

下载PDF

导出

摘要目的探讨外周血T淋巴细胞亚群检测在恶性肿瘤患者中的临床价值。方法选择2011年4月～2011年10月期间本院诊治的100例恶性肿瘤患者为观察对象,另选50例正常人(来自体检中心健康体检者)作为对照组,采用流式细胞术于治疗前、后检测其外周血CD3+、CD4+、CD8+T细胞及CD4+/CD8+比值水平,并进行统计学分析。结果与对照组相比,肿瘤组治疗前、后的CD3+、CD4+、CD4+/CD8+比值均明显降低;与治疗前相比,肿瘤组治疗后CD3+、CD4+、CD4+/CD8+比值均明显升高,P<0.05,差异有统计学意义。结论对于恶性肿瘤患者,检测外周血T细胞亚群,对判定临床疗效及预后,具有重要的临床意义。

作者冯利得

机构地区河南省安阳市中医院

出处《当代医学》 2012年第3期111-113,共3页 Contemporary Medicine

关键词外周血T淋巴细胞亚群恶性肿瘤 CD4+/CD8+比值

分类号 R730.4 [医药卫生—肿瘤]

引文网络
相关文献

参考文献3

1吴映娥,蔡应木,李康生.恶性肿瘤患者外周血T细胞亚群的检测及其临床意义[J].中国校医,2007,21(2):209-211. 被引量：14
2杨曌,牛微,尚小云,吴玉章,赵建平,王莉.肝癌患者CD4^+CD25^+调节性T细胞的检测及其临床意义[J].中国癌症杂志,2007,17(1):62-64. 被引量：12
3邵明海,王建华,丁维军,胡炜,王碧云.恶性肿瘤患者外周血CD_4^+CD_(25)^+调节性T细胞的检测及其临床意义[J].现代实用医学,2009,21(2):142-143. 被引量：19

二级参考文献31

1刘莉,丁乾,曹如波,王晶,姚军霞,黄士昂.恶性肿瘤患者外周血CD4^+ CD25^+调节T细胞的检测及其临床意义[J].临床肿瘤学杂志,2005,10(4):342-345. 被引量：16
2Itoh M, Takahashi T, Sakaguchi, et al. Thymus and autoimmunity: production of CD4^+ CD25^+ naturally anergic and suppressive T cells as a key function of the thymus in mainraining immunologic self-tolerance[J]. J Immunol,1999,162(9):5317-5326.
3Seo N, Hayakawa S, Taldgawa M, et al. Interleukin-10 expressed at early tumour sites induces subsequent generation of CD4^+ T regulatory cells and systemic collapse of antitumour immunity[J]. Immunology,2001,103 (4): 449 - 457.
4Horwitz DA, Zheng SG, Gray JD. The role of the combination of IL-2 and TGF-beta or IL-10 in the generation and function of CD4^+CD25^+ and CD8 regulatory T cellsubsets [J]. J Leukoc Bioi,2003,74(4): 471-478.
5Bopp T, Palmetshofer A, Settling E, et al. NFATc2 and NFATc3 transcription factors play a crucial role in suppression of CD4^+ T lymphocytes by CD4^+CD25^+ regulatory T cells [J]. J Exp Med,2005,201(2): 181 - 187.
6Baecher-Allan C, Brown J A, Freeman G J, et al. CD4^+high CD25^+ regulatory cells in human peripheral blood[J].J Immunol,2001,167(3): 1245-1253
7Sasada T, Kimura M, Yoshida Y, et al. CD4^+CD25^+ regulatory T cells in patients with gastrointestinal malignancies: possible involvement of regulatory T cells in disease progression [J] .Cancer ,2003,98 (5): 1089-1099.
8Tanaka H, Tanaka J, Kjaergaard J, et al. Depletion of CD4^+CD25^+ regulatory cells aug- ments the generation of specific immune T cells in tumor-draining lymph nodes[J]. J Immunother,2002,25(3): 207 - 217.
9Nagai H, Horikawa T, Hara I, et al. In vivo elimination of CD25^+ regulatory T cellleads to tumor rejection of B 16F 10 melanoma, when combined with interleukin-12 gene transfer [J]. Exp Dermatol,2004,13(10):613 - 620.
10Llovet JM, Burroughs A, Bruix J, et al. Hepatocellular carcinoma[J]. Lancet,2003, 362: 1907-1917.